PPCB — Propanc Biopharma Balance Sheet
0.000.00%
- $0.04m
- $1.23m
Annual balance sheet for Propanc Biopharma, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 0.067 | 0.002 | 0.004 | 0.01 | 0.021 |
Net Total Receivables | 0.002 | 0.004 | 0.002 | 0.003 | 0.003 |
Prepaid Expenses | |||||
Total Current Assets | 0.069 | 0.007 | 0.015 | 0.019 | 0.025 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.027 | 0.004 | 0.065 | 0.039 | 0.018 |
Other Long Term Assets | |||||
Total Assets | 0.099 | 0.013 | 0.082 | 0.06 | 0.072 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.74 | 3.08 | 3.06 | 3.16 | 3.79 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 3.74 | 3.08 | 3.11 | 3.18 | 3.85 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | -3.64 | -3.07 | -3.02 | -3.12 | -3.78 |
Total Liabilities & Shareholders' Equity | 0.099 | 0.013 | 0.082 | 0.06 | 0.072 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |